Influence of morphine on pharmacokinetics and pharmacodynamics of ticagrelor in patients with acute myocardial infarction (IMPRESSION): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Kubica, Jacek ^a   Adamski, Piotr ^a   Ostrowska, Małgorzata ^a   Koziński, Marek ^a   Obońska, Karolina ^a   Laskowska, Ewa ^a   Obońska, Ewa ^a   Grześk, Grzegorz ^a   Winiarski, Piotr ^b   Paciorek, Przemysław ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Department of Urology   (Poland)

Author keywords

Morphine; Myocardial infarction; Pharmacodynamics; Pharmacokinetics; Ticagrelor

Indexed keywords

MORPHINE; PLACEBO; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; AR C124910XX; NARCOTIC ANALGESIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; HUMAN; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PHASE 4 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE FUNCTION; AGED; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL PROTOCOL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG INTERACTION; DRUG MONITORING; FEMALE; MALE; METABOLISM; METHODOLOGY; MYOCARDIAL INFARCTION; PHASE 4 CLINICAL TRIAL; POLAND; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; TREATMENT OUTCOME;

ADENOSINE; AGED; ANALGESICS, OPIOID; BIOTRANSFORMATION; BLOOD PLATELETS; CHROMATOGRAPHY, LIQUID; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MORPHINE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLAND; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84928879598     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0724-z     Document Type: Article

References (14)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
2. Navarese EP, Buffon A, Kozinski M, Rychter M, Obonska K, Kunadian V, et al. A critical overview on ticagrelor in acute coronary syndromes. QJM. 2013;106:105-15.
3. Navarese EP, Verdoia M, Schaffer A, Suriano P, Kozinski M, Castriota F, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM. 2011;104:561-9.
4. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
5. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
6. O'Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, De Lemos J, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv. 2013;82:E1-27.
7. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey Jr DE, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645-81.
8. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043-9.
9. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63:630-5.
10. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-6.
11. Kubica A, Kasprzak M, Siller-Matula J, Koziński M, Pio Navarese E, Obońska K, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014;742:47-54.
12. Koziński M, Obońska K, Stankowska K, Navarese EP, Fabiszak T, Stolarek W, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J. 2014;21:547-56.
13. Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, et al. Diurnal variation in the platelet inhibition by clopidogrel. Platelets. 2011;22:579-87.
14. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-73.